Bayer's Stivarga Divestment and Pipeline Progress Take a Back Seat to Washington Legal Clouds

Bayer stock closed at EUR 45.02, down 10% over seven days, as unresolved US glyphosate litigation outweighed Stivarga sale and FDA progress.

A familiar pattern is reasserting itself for Bayer shareholders: operational housekeeping and regulatory wins keep coming, yet the American glyphosate litigation continues to set the tone for the stock. Disappointment that a near-term resolution to the long-running US dispute has failed to materialize weighed on the Leverkusen group's shares on Thursday, with selling pressure building through the session.

Market participants pointed to persistent legal and regulatory risks in the United States as the mood dampener, though no single fresh catalyst was identified as the trigger. By the end of the week the stock closed at EUR 45.02, a decline of 10% over a seven-day stretch. The episode underscores how heavily the North American courtroom battles still shape how investors value the company. Bayer has clawed back ground from earlier lows during the year, but stretches of legal uncertainty repeatedly force a more cautious read on the shares.

Portfolio Moves and Regulatory Milestones

The legal backdrop has largely overshadowed the initiatives Bayer is pushing on other fronts. On 21 September the company agreed to sell the worldwide rights to its cancer drug Stivarga to pharmaceutical firm Grünenthal, in a deal carrying a transaction value of up to EUR 375 million. Completion is targeted for late 2026 or early 2027, subject to regulatory approvals.

Progress on the development side has also continued. The US Food and Drug Administration granted accelerated review to the active ingredient Lynkuet for an additional indication, while development projects at subsidiary BlueRock Therapeutics picked up special designations in both the US and Europe. On the organizational front, Dr. Christoph Koenen took on the role of Chief Medical Officer of the pharmaceutical division alongside his existing duties, tasked with steering the segment's medical strategy. Against the dominant caution over the legal situation, these operational moves drew little response from the market.

Analyst View and Ownership Shift

Deutsche Bank Research offered a concrete read on the upcoming interim report on 29 September. Analyst Virginie Boucher-Ferte rated the stock "Buy" with a price target of EUR 60. For the third quarter of 2026, she projects operating revenue growth of 1.3% year on year, while expecting headwinds at the operating profit line, where she forecasts a 10% decline.

Shareholder registers saw movement as well: French asset manager Amundi fell below the 3% voting rights notification threshold in the DAX-listed group on 23 September.

What to Watch on 3 November

Investors will get clarity on actual business performance in early November. Bayer plans to publish its full third-quarter results on 3 November at 07:30 CET, with an earnings call to discuss the figures scheduled for 14:00 CET the same day.

Despite the recent consolidation, the stock remains up 22% since the start of the year. Whether that upward trend holds through the full year will depend heavily on the detailed business reports and further developments in the agricultural sector. On the chart, the shares are trading 4.5% above their 200-day moving average of EUR 43.09, leaving a buffer to the long-term trend line even after the latest swings.